Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: A comprehensive cytokine-phenotype study

Leukemia

Volumn 27, Issue 6, 2013, Pages 1430-1433

  Pardanani, A ^a   Finke, C ^a   Abdelrahman, R A ^a   Lasho, T L ^a   Hanson, C A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LETTER; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; SYSTEMIC MASTOCYTOSIS; WORLD HEALTH ORGANIZATION;

FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MASTOCYTOSIS; PHENOTYPE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84878899137     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.11     Document Type: Letter

References (14)

1. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th edn. (International Agency for Research and Cancer (IARC): Lyon, 2008, pp 54-63.
2. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-5736.
3. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-521.
4. Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010; 115: 150-151.
5. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
6. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA et al. IPSSindependent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2012; 26: 693-699.
7. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012; 87: 865-869.
8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
9. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS, Scott LM et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000; 96: 1267-1273. (Pubitemid 30658453)
10. Morgado JM, Sanchez-Munoz L, Teodosio CG, Jara-Acevedo M, Alvarez-Twose I, Matito A et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012; 25: 516-521.
11. Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases-a review. Med Sci Monit 2008; 14: RA179-RA189.
12. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604-608. (Pubitemid 38725760)
13. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011; 118: 2809-2820.
14. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Munoz L, Almeida J et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26: 951-958.